Prognostic significance of tumour infiltrating lymphocytes in different molecular subtypes of invasive breast carcinoma
- Authors: Tashireva L.A1, Lyapunova L.S1, Buzenkova A.V1, Pankova O.V1, Zavyalova M.V1,2, Perelmuter V.M1
-
Affiliations:
- Cancer Research Institute Tomsk National Research Medical Centre
- Siberian State Medical University
- Issue: Vol 15, No 2 (2020)
- Pages: 89-95
- Section: Articles
- URL: https://genescells.ru/2313-1829/article/view/122066
- DOI: https://doi.org/10.23868/202004021
- ID: 122066
Cite item
Open Access
Access granted
Abstract
Metastasis is the main cause of death from cancer, including breast cancer, so the search for simple and effective prognostic parameters is becoming a priority for researchers. The number of tumor-infiltrating lymphocytes is a proven prognostic factor for triple negative and Her2-positive, but not luminal, molecular subtypes of breast cancer. Possible reasons for the failure of this prognostic parameter for luminal subtypes of breast cancer may be the tumor morphological heterogeneity. Objective: to assess the prognostic significance of the tumor-infiltrating lymphocytes number in the invasive breast carcinoma of a non-specific type (IC NST) of various molecular subtypes, taking into account its morphological heterogeneity. 152 patients with IC NST (T1-3N0-2M0) aged 29 to 75 years were enrolled in the study. The molecular subtype was determined using immunohistochemical analysis of the expression of estrogen and progesterone receptors, Ki-67 and Her2/neu. TILs were assessed in accordance with the recommendations of the International TILs Working Group. It was shown that TILs near the structures of various types is heterogeneous only in patients with the luminal Her2-negative subtype of IC NST. In addition, was found that the development of hematogenous metastases and worse metastatic-free survival in this cohort of patients is associated with a high TILs near solid structures and also depended on Ki-67 level. Thus, TILs near solid structures is a potential prognostic factor for the development of distant metastasis in the luminal Her2-negative and Ki-67 level less 20% subtype of IC NST.
Full Text
About the authors
L. A Tashireva
Cancer Research Institute Tomsk National Research Medical Centre
Email: tashireva@oncology.tomsk.ru
Tomsk, Russia; Tomsk, Russia
L. S Lyapunova
Cancer Research Institute Tomsk National Research Medical CentreTomsk, Russia; Tomsk, Russia
A. V Buzenkova
Cancer Research Institute Tomsk National Research Medical CentreTomsk, Russia; Tomsk, Russia
O. V Pankova
Cancer Research Institute Tomsk National Research Medical CentreTomsk, Russia; Tomsk, Russia
M. V Zavyalova
Cancer Research Institute Tomsk National Research Medical Centre; Siberian State Medical UniversityTomsk, Russia; Tomsk, Russia
V. M Perelmuter
Cancer Research Institute Tomsk National Research Medical CentreTomsk, Russia; Tomsk, Russia
References
- Salgado R., Denkert C., Demaria S. et al. International TILs Working Group 2014. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann. Oncol. 2015; 26(2): 259-71.
- Loi S., Michiels S., Salgado R. et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastu-zumab benefit in early breast cancer: results from the FinHER trial. Ann. Oncol. 2014; 25(8): 1544-50.
- Loi S., Sirtaine N., Piette F. et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J. Clin. Oncol. 2013; 31(7): 860-7.
- Denkert C., von Minckwitz G., Brase J.C. et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J. Clin. Oncol. 2015; 33(9): 983-91.
- Balic M., Thomssen C., Würstlein R. et al. St. Gallen/Vienna 2019: A brief summary of the consensus discussion on the optimal primary breast cancer treatment. Breast Care 2019; 14: 103-10.
- Jang N., Kwon H.J., Park M.H. et al. Prognostic value of tumor-infiltrating lymphocyte density assessed using a standardized method based on molecular subtypes and adjuvant chemotherapy in invasive breast cancer. Ann. Surg. Oncol. 2018; 25(4): 937-46.
- Denkert C., von Minckwitz G., Darb-Esfahani S. et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018; 19(1): 40-50.
- Завьялова М.В., Телегина Н.С., Вторушин С.В. и др. Особенности морфологического строения люминального А типа рака молочной железы. Сибирский онкологический журнал 2013; 1: 38-41.
- Gerashchenko T.S., Denisov E.V., Litviakov N.V. et al. Intratumor heterogeneity: nature and biological significance. Biochemistry (Moscow) 2013; 78(11): 1201-15.
- Bloom H.J., Richardson W.W. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br. J. Cancer 1957; 11(3): 359-77.
- Coates A.S., Winer E.P., Goldhirsch A. et al. Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann. Oncol. 2015; 26: 1533-46.
- Zavyalova M.V., Denisov E.V., Tashireva L.A. et al. Phenotypic drift as a cause for intratumoral morphological heterogeneity of invasive ductal breast carcinoma not otherwise specified. BioResearch Open Access 2013; 2(2): 148-54.
- Геращенко Т.С., Денисов Е.В., Литвяков Н.В. и др. Внутриопухолевая гетерогенность: природа и биологическое значение (обзор). Биохимия 2013; 78(11): 1531-49.
- Перельмутер В.М., Таширева Л.А., Манских В.Н. и др. Иммуновоспалительные реакции в микроокружении гетерогенны, пластичны, определяют противоопухолевый эффект или агрессивное поведение опухоли. Журнал общей биологии 2017; 78(5): 15-36.
- Gooden M.J., de Bock G.H., Leffers N. et al. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with metaanalysis. Br. J. Cancer 2011; 105(1): 93-103.
- Fujimoto Y., Watanabe T., Hida A.I. et al. Prognostic significance of tumor-infiltrating lymphocytes may differ depending on Ki67 expression levels in estrogen receptor-positive/HER2-negative operated breast cancers. Breast Cancer 2019: 1-10.
Supplementary files
